血液透析起始后炎症标志物的双相动态变化:国际透析结局监测倡议(MONDO)研究结果
该研究基于MONDO联盟31个国家血液透析数据库,纳入18726例新起始血液透析患者,按月检测白细胞计数、中性粒细胞计数、淋巴细胞计数、血清白蛋白、C反应蛋白及血红蛋白。死亡患者呈现炎症标志物先降后升的双相模式,快速上升约在死亡前6个月持续出现;存活超过36个月者则为初始下降后持续低水平。
要点
- 死亡患者炎症标志物呈双相变化:初始下降后快速上升,约在死亡前6个月持续可见。
- 存活超过36个月患者为初始炎症下降后持续低水平。
- 该双相模式在所有死亡患者中相似,且在各生存时间区间内一致。
核心结论
- 新起始血液透析患者系列炎症标志物测量与患者生存之间存在时间关系,该发现可能有助于预后模型开发,如将炎症标志物动态变化纳入个体化风险分层并指导预防和治疗干预。
研究设计与样本
- MONDO联盟涵盖欧洲、北美、南美和亚洲31个国家的血液透析数据库,查询新起始血液透析患者的炎症标志物和血红蛋白水平,实验室参数每月测量。
- 共研究18726例新起始血液透析患者,透析起始时年龄71.3±11.9岁,男性10802例(58%)。
- 患者按透析起始后生存时间分层:≤6个月、>6至12个月、>12至18个月、>18至24个月、>24至30个月、>30至36个月及>36个月。
- 使用三次B样条基函数评估炎症参数随时间变化与患者生存的关系。
主要发现
- 前6个月内2068例(11%)患者死亡,12295例(67%)存活超过36个月(存活者队列)。
- 死亡患者显示炎症标志物变化的独特双相模式:初始炎症下降后快速上升,约在死亡前6个月持续可见。
- 该模式在所有死亡患者中相似,且在各生存时间区间内一致。
- 存活者队列中观察到炎症初始下降后炎症生物标志物持续低水平。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Inflammation is highly prevalent among patients with end-stage kidney disease and is associated with adverse outcomes. We aimed to investigate longitudinal changes in inflammatory markers in a diverse international incident hemodialysis patient population. METHODS: The MONitoring Dialysis Outcomes (MONDO) Consortium encompasses hemodialysis databases from 31 countries in Europe, North America, South America, and Asia. The MONDO database was queried for inflammatory markers (total white blood cell count [WBC], neutrophil count, lymphocyte count, serum albumin, and C-reactive protein [CRP]) and hemoglobin levels in incident hemodialysis patients. Laboratory parameters were measured every month. Patients were stratified by survival time (≤6 months, >6 to 12 months, >12 to 18 months, >18 to 24 months, >24 to 30 months, >30 to 36 months, and >36 months) following dialysis initiation. We used cubic B-spline basis function to evaluate temporal changes in inflammatory parameters in relationship with patient survival. RESULTS: We studied 18,726 incident hemodialysis patients. Their age at dialysis initiation was 71.3 ± 11.9 years; 10,802 (58%) were males. Within the first 6 months, 2068 (11%) patients died, and 12,295 patients (67%) survived >36 months (survivor cohort). Hemodialysis patients who died showed a distinct biphasic pattern of change in inflammatory markers where an initial decline of inflammation was followed by a rapid rise that was consistently evident approximately 6 months before death. This pattern was similar in all patients who died and was consistent across the survival time intervals. In contrast, in the survivor cohort, we observed initial decline of inflammation followed by sustained low levels of inflammatory biomarkers. CONCLUSION: Our international study of incident hemodialysis patients highlights a temporal relationship between serial measurements of inflammatory markers and patient survival. This finding may inform the development of prognostic models, such as the integration of dynamic changes in inflammatory markers for individual risk profiling and guiding preventive and therapeutic interventions.
引用
- Yousif DE, Ye X, Stuard S, et al. Biphasic Dynamics of Inflammatory Markers Following Hemodialysis Initiation: Results From the International MONitoring Dialysis Outcome Initiative. Kidney Int Rep. 2022. PMID: 36644346. doi:10.1016/j.ekir.2022.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。